SLUCare Selects Medial EarlySign Artificial Intelligence to Predict Patients at Risk for Lower GI Disorders
Similar Posts
PathAI Announces IBD Explore, an AI-powered Histopathology Panel to Unlock Insights for Ulcerative Colitis from the Inflammatory Microenvironment
PathAI’s IBD Explore™ panel will empower drug developers with improved inflammatory microenvironment spatial characterization from H&E, propelling a…
